Based on the research goals and strategies for this project, the alliance partnerships and collaborations of multi-institutes and multi-disciplines networks have been established from 2004 to 2008. The major research platform technologies of this project include nano-drug delivery technologies, molecular bio-targeted technologies, radiochemistry and targeted radionuclide technologies, in vivo molecular imaging technologies.
The current major research and development progress and achievements including:
- Complete the preparation and characterization of two passive nano-targeted radiopharmaceuticals of 111In-liposome and 188Re-liposome, two passive dual-modality nano-targeted therapeutics of 111In-VNB-liposome and 188Re-DXR-liposome.
- Complete and proceed preclinical studies of drugs in vitro stability, pharmacokinetics, biodistribution and radiation dosimetry studies of those drugs on HT-29/CT-26 tumor and ascites animal models .
- Apply whole-body autoradiography, in vivo nuclear and optical molecular imaging techniques to study HT-29/CT-26 tumors and ascites targeting, targeted therapeutic efficacy and therapeutic response.
The tumor regression, the therapeutic efficacy of auger electron and β radiation of 111In-liposome and 188Re-liposome, the combination additive or synergistic effect of radio-chemotherapy with dual-modality nano-targeted 111In-VNB-liposome/188Re-DXR-liposome have been demonstrated. For establishment the best novel dual functional nano-targeted diagnostics and therapeutics and dual modality therapeutics to treat tumors and malignant ascites and translation from preclinical to clinical studies, new site specific passive targeted 188Re/111In-liposome (β and γ radionuclides), active molecular specific targeting EGFR antibody radioconjugates and specific multivalent targeting nano-immunoliposomes will be studied, compared and optimized from pharmacology to toxicology with murine and human tumor and ascites animal models in this investigations.
With the successful integration and collaborations of five research/education/industry institutes, three patents have been filed in US and ROC in 2007-2008, five SCI journal papers have been published from 2004 to 2007, and additional five SCI papers will be submitted and published in 2008, 16 oral and poster papers have been accepted and presented in the international symposium from 2004 to 2008.